Tango I was a randomised, double-blind, double-dummy trial that compared meropenem with vaborbactam (2 g/2 g IV [intravenous] over 3 hours, every 8 hours) with piperacillin with tazobactam (4 g/0.5 g ...

• Meropenem and vaborbactam injection is available as a powder for reconstitution which has to be mixed with 0.9% sodium chloride injection. • Mix the contents of the vial gently and dilute further ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration (FDA) has approved VABOMERE™ (meropenem and vaborbactam) for injection ...

Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections The first combination of a carbapenem and a ...

Please provide your email address to receive an email when new articles are posted on . Gram-negative bacillary (GNB) resistance is increasing worldwide, leaving clinicians with challenging treatment ...

The results showed that meropenem/vaborbactam was non-inferior to piperacillin/tazobactam with an overall success rate of 98.4% vs 94.0%. Results from the Phase 3 ...

Review the side-effects of Meropenem and Vaborbactam as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

image of bacteria Overall treatment success occurred in 98.4% of patients receiving meropenem-vaborbactam vs 94% for those receiving piperacillin-tazobactam. Meropenem-vabobactam, a combination ...

The content of this evidence review was up-to-date in November 2019. See summaries of product characteristics (SPCs), British national formulary (BNF), or the Medicines and Healthcare products ...